All In Biotech

Drug Trial Radar · NCT00512135

Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

A Prospective, Open-label, Multicenter, Repeat-dose Trial to Investigate the Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines

Last checked: Nov 20, 2026Latest source record: Apr 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

801

Actual

Start

Jun 18, 2007

Primary completion

Dec 28, 2009

Study completion Dec 28, 2009

Sponsor

Lead sponsor
Merz Pharmaceuticals GmbHIndustry
Sponsor type
Industry
First posted
Aug 7, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study objective was to investigate the safety and efficacy of incobotulinumtoxinA (Xeomin) during repeat dose treatment of glabellar frown lines. 801 participants with moderate to severe glabellar frown lines at maximum frown who completed participation in one of the studies in this program, i.e. MRZ 60201-0520/1, MRZ 60201-0527/1, MRZ 60201-0724/1, or MRZ 60201-0741/1 were eligible to participate in this repeat-dose study.

Conditions

  • Glabellar Lines

Interventions

  • IncobotulinumtoxinA (Xeomin) (20 units)Drug

    Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: Baseline up to Month 30
  2. Incidence of Adverse Events of Special Interest (AESI)Time frame: Baseline up to Month 30
  3. Percentage of Responders at Maximum Frown as Assessed by the Investigator According to Facial Wrinkle Scale (FWS)Time frame: At evaluation visit (30 days after injection) and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
  4. Percentage of Responders at Rest as Assessed by the Investigator According to FWSTime frame: At evaluation visit (30 days after injection) and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
  5. Percentage of Responders at Maximum Frown by Participant's Assessment on the 4-point ScaleTime frame: At evaluation visit (30 days after injection) and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
  6. Percentage of Responders at Rest by Participant's Assessment on the 4-point ScaleTime frame: At evaluation visit (30 days after injection) and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
  7. Degree of Glabellar Lines as Assessed by the Participant on the 6-point Likert Type Scale at Maximum FrownTime frame: At evaluation visit (30 days after injection); and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
  8. Degree of Glabellar Lines as Assessed by the Participant on the 6-point Likert Type Scale at RestTime frame: At evaluation visit (30 days after injection); and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
  9. Time to Onset of Treatment EffectTime frame: From injection visit up to date of onset of treatment effect in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)

Locations

25 sites in 3 countries. Site status is shown where the registry gives one.

  • Skin Care Centre

    Los Angeles, California

  • About Skin Dermatology

    Englewood, Colorado

  • Centre for Cosmetic Enhancement

    Aventura, Florida

  • Brandt

    Coral Gables, Florida

  • Advanced Dermatology Research Institute

    Lincolnshire, Illinois

  • Laser &Skin Surgery Center of Indiana

    Carmel, Indiana

  • Coleman

    Metairie, Louisiana

  • Skin Care Physisians of Chestnut Hill

    Chestnut Hill, Massachusetts

  • Schlessinger

    Omaha, Nebraska

  • Image Dermatology P.C.

    Montclair, New Jersey

  • Narins

    White Plains, New York

  • Flynn Consulting PLLC

    Raleigh, North Carolina

  • Tennessee Clinical Research Center

    Nashville, Tennessee

  • Carruthers Dermatology Centre Inc.

    Vancouver, British Columbia, Canada

  • Solish

    Toronto, Ontario, Canada

  • Charité Berlin - Klinik für Dermatologie

    Berlin, Germany

  • Rosenparkklinik

    Darmstadt, Germany

  • Krankenhaus Dresden Friedrichstadt

    Dresden, Germany

  • Johann-Wolfgang-Goethe- Universitätsklinikum Frankfurt

    Frankfurt am Main, Germany

  • Universität Hamburg

    Hamburg, Germany

  • SCIderm GmbH

    Hamburg, Germany

  • Uniklinik Saarland

    Homburg / Saar, Germany

  • Dr. Michael Sebastian

    Mahlow, Germany

  • Dr. Hans-Ulrich Voigt

    München, Germany

  • Dr. Thomas Dirschka

    Wuppertal, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.